Bethany A. Danner, NP

Richard Burkhart, M.D., is an Associate Professor of Surgery at The Johns Hopkins Hospital with a focus on complex minimally-invasive surgery and research for cancers of the pancreas, liver and bile ducts. Dr. Burkhart received his medical degree from Boston University and completed his surgical residency and research fellowships at the Thomas Jefferson University Hospital in Philadelphia and the Cold Spring Harbor Laboratories. He is a member of several professional organizations, including the American Association of Cancer Research, the American College of Surgeons, the Society of Surgery for the Alimentary Tract, the Pancreas Club, and the Society of Surgical Oncology. Outside the operating room, Dr. Burkhart heads a multidisciplinary laboratory team dedicated to bringing next-generation precision medicine approaches into the routine clinical care of patients that we serve. He has a particular research interest in using personalized models of pancreas cancer, made from tumor during and immediately after surgical resection, to select the best chemotherapy for each patient to support long-term survival and improve rates of disease cure. The laboratory team, funded in part by the National Institutes of Health, the National Cancer Institute, the Lustgarten Foundation and Stand Up to Cancer, is also thankful to the many patients who have supported the work through philanthropic gift. Dr. Burkhart is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Burkhart is board certified in American Board Of Surgery. Dr. Burkhart is currently accepting new patients.

David Euhus is a Surgical Oncologist practicing medicine in Baltimore, Maryland. Dr. Euhus is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Lymphadenectomy.

Dr. Topalian is a physician-scientist whose studies of anti-tumor immunity have been foundational in developing cancer immunotherapy. She has published over 160 original research articles and reviews in this area and is one of the most highly cited researchers in the biomedical field. She received her medical and scientific training at Tufts University School of Medicine, Thomas Jefferson University Hospital, Children’s Hospital of Philadelphia and the National Cancer Institute. She joined the Johns Hopkins Kimmel Cancer Center in 2006 as the inaugural director of its Melanoma Program. Dr. Topalian is credited with advancing the clinical development of anti-PD-1 immunotherapy, and her work is widely recognized. She was named one of Nature’s 10 in 2014, and received the Karnofsky Award from ASCO in 2015, the Taubman Prize in 2016, the NCI’s Rosalind E. Franklin Award in 2018, the American Academy of Dermatology’s Gruber Memorial Cancer Research Award in 2020, and the Award for Distinguished Research in the Biomedical Sciences from the Association of American Medical Colleges in 2021 for landmark discoveries in cancer immunotherapy. Dr. Topalian was elected to the National Academy of Medicine in 2017, and to the American Association for Cancer Research Academy in 2022. Her work has opened new avenues of scientific investigation and established immunotherapy as a pillar of oncology. Dr. Topalian is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Merkel Cell Carcinoma, Melanoma, and Neuroendocrine Tumor. Dr. Topalian is currently accepting new patients.